Absci Corporation Common Stock Q2 2026 Earnings Recap

Absci’s shares rose 5.4% following interim Phase I data that demonstrated favorable safety and pharmacokinetics for ABS-201, underpinning optimism around its potential dosing schedule and the strategic partnership with Eli Lilly.

Key Takeaways

• Interim Phase I data show ABS-201 was well tolerated with a favorable safety and immunogenicity profile.
• Pharmacokinetic results estimate a half-life of at least 65 days, supporting a dosing regimen of 2 to 3 injections over six months.
• Strategic $40 million investment from Eli Lilly strengthens collaboration and includes Lilly participation on Absci’s endometriosis advisory board.
• Absci completed a $100 million financing round, enabling ongoing development and pipeline expansion.
• The Atlas platform is actively generating novel target hypotheses, including new indications for the prolactin receptor franchise, reflecting progress in leveraging AI-driven discovery.